VivoSeq
Oncology

Patients With Locally Advanced Rectal Cancer

0

Pipeline Programs↗

9

Active Trials↗

3

Companies Involved↗

Patients With Locally Advanced Rectal Cancer is an early-stage landscape with 0 programs across 3 companies. The most active players are AbbVie, Trans Tasman Radiation Oncology Group, Roche.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

85/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

0 programs

PreclinicalT

Trans Tasman Radiation Oncology Group

0 programs

PreclinicalRoche logo

Roche

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

26

clinical trials

Completed11 · 42%
Recruiting4 · 15%
Unknown status4 · 15%
Not yet recruiting3 · 12%
Active, not recruiting2 · 8%
Terminated2 · 8%

Clinical Trials

Trial Activity

26 trials

Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer
Recruiting·JJules Bordet Institute·N/A·NCT06052332·230 enrolled
SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer
Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06864013·116 enrolled
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
Recruiting·—·Phase 3·NCT04495088·550 enrolled
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Recruiting·WWashington University School of Medicine·Phase 1/2·NCT03516708·49 enrolled
GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.
Active, not recruiting·GGrupo Espanol Multidisciplinario del Cancer Digestivo·N/A·NCT05674422·120 enrolled
Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02008656·358 enrolled
An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer
Not yet recruiting·FFudan University·Phase 2·NCT04443543·222 enrolled
Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial (NeoCaCRT-III)
Not yet recruiting·—·Phase 3·NCT06832917·238 enrolled
A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
Not yet recruiting·—·Phase 2·NCT07239466·48 enrolled
Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer
Completed·FFox Chase Cancer Center·Phase 1·NCT00084591
A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
Completed·AbbVie logoAbbVie·Phase 1·NCT01589419·32 enrolled
A Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer
Completed·YYonsei University·Phase 2·NCT01269216·136 enrolled
Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer
Completed·—·Phase 2·NCT03443661·50 enrolled
Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer
Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT00462501·35 enrolled
Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer
Completed·TTrans Tasman Radiation Oncology Group·Phase 2·NCT01013805·41 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)